Skip to main content
  • Offering
    • Offering
    • Integrated Biologics
      • Integrated Biologics
      • Expression Technologies
        • Expression Technologies
        • GS Xceed® Gene Expression System
        • GS piggyBac® Transposon Technology
        • GS Effex® Cell Line
        • GS Discovery® Transient Expression
        • bYlok® Bispecific Pairing Technology
        • XS Technologies® Platform
        • Technical Support
      • Early Derisking and Optimization
        • Early Derisking and Optimization
        • Developability Assessment
        • Manufacturability Assessment
        • Immunogenicity / Immunotoxicity Assessment
        • ​​Early Protein Expression​​​ Services​​
      • Integrated DNA-to-IND Programs
        • Integrated DNA-to-IND Programs
        • mAbs DNA-to-IND Program
        • Bispecifics DNA-to-IND Program
        • Fabs and Fc-Fusion Proteins DNA-to-IND Programs
        • Scaffolds and other Recombinant Proteins
      • Manufacturing
        • Manufacturing
        • Mammalian Drug Substance Manufacturing
        • Drug Product Manufacture
      • Mammalian Biopharmaceutical Services
        • Mammalian Biopharmaceutical Services
        • Cell Line Development
        • Tailored License Application Program
        • Process Development
        • Analytical Development
      • Parenteral Drug Product Services
        • Parenteral Drug Product Services
        • Clinical Technology Transfers
        • Biologics Formulatability
        • Product Formulation Development
        • Analytics
        • Process Development
        • Biologics Special Services
        • Large-scale Manufacturing Expansion
      • Biologics Regulatory Affairs Services
      • Knowledge Center
    • Advanced Synthesis
      • Advanced Synthesis
      • Small Molecules
        • Small Molecules
        • Drug Substance/API Services
          • Drug Substance/API Services
          • Accelerate Early Drug Development with Lonza Design2Optimize®
          • Early Phase Small Molecule Development Services
          • API Support for Early Phase Development
          • AI-Enabled Route Scouting Service
          • Solid Form Drug Services
          • PBPK Modeling Services
          • High-Throughput Experimentation (HTE) | Accelerate Chemical Optimization with Lonza
          • Pharmaceutical Method Development
          • Commercial API Manufacturing Services
          • Highly Potent API Technologies
            • Highly Potent API Technologies
            • HPAPI Handling and Development
            • HPAPI Manufacturing | Low & High Potency
          • ADC Clinical and Commercial Manufacturing
          • ADC Payload Product Development
        • Particle Engineering
          • Particle Engineering
          • Solid Dispersion Technology
          • Bioavailability Enhancement
          • Spray-Dried Dispersion Technology
        • Drug Product
          • Drug Product
          • Clinical Trial Material Manufacture, Supply
          • Formulation and Development
          • Design and Preformulation Development
          • Drug Development Workflow & Pharmaceutical Process Optimization
          • Inhalation Formulation Development
          • Integrated Offerings
        • Regulatory Affairs CMC Services
          • Regulatory Affairs CMC Services
          • CMC Development Services | CMC Regulatory Submissions
      • Bioconjugation Services
        • Bioconjugation Services
        • Early Development Bioconjugate Services | ADCs
        • ADC Drug Substance Manufacturing
        • Pharmaceutical, ADC Analytical Services
        • Targeting Agent and Carrier Protein
        • ADC Process Development
        • Ibex® Design ADC, DNA-to-IND Program
      • ADC Technologies Platform
      • Knowledge Center
    • Specialized Modalities
      • Specialized Modalities
      • Cell & Gene
        • Cell & Gene
        • Process Development
        • cGMP Manufacturing
        • Allogeneic
        • Autologous
        • Viral Vectors
        • Exosomes
      • Microbial
        • Microbial
        • Microbial Strain Development
        • Process Development
        • Drug Substance Manufacturing
        • Analytical Development
      • mRNA/LNP
        • mRNA/LNP
        • Process Development
        • Analytical Services
        • mRNA Manufacturing
        • Lipid Nanoparticles Encapsulation
      • Bioscience Products
      • Knowledge Center
    • Knowledge Center
  • Company
    • Company
    • About Us
      • About Us
      • Our One Lonza Strategy
      • Our Leadership
        • Our Leadership
        • Executive Committee
        • Board of Directors
        • Board Committees
      • Our History
      • Our Locations
    • News and Media
      • News and Media
      • News Releases
      • Images and Videos
      • Logo Guidelines
      • Blog
      • A View On - Lonza Podcast
      • Journalist Inquiries
    • Investor Relations
      • Investor Relations
      • Shareholder and Bondholder Information
        • Shareholder and Bondholder Information
        • Consensus and Analysts
        • Bond Investors and Credit Information
        • Investor FAQ
        • Share Buyback
      • Agenda and Events
      • Reporting and Presentations
      • Corporate Governance
      • Ethics and Compliance
      • Investor Inquiries and Feedback
    • Sustainability
      • Sustainability
      • Environment
      • People and Society
      • Compliance and Integrity
      • Responsible Sourcing
      • Global Quality
  • Careers
    • Careers
    • Welcome to Lonza
    • Life at Lonza
    • Employee Benefits
    • Early Career Opportunities
    • Inclusion, Diversity and Belonging
    • Join Our Talent Community
  • Contact Search
  • Cancel

Sustainability News Archive

  • Home
  • News and Media
  • News Releases
  • Sustainability News Archive
Filter Results
Filter Results
Filter by Year
2024 (2) 2023 (1)
   Loading...
Showing 1‐3 of 3
Media Advisory
17 Apr 2024
Lonza Signs Multiple Renewable Energy Certificate Agreements in the United States
Lonza signs three Renewable Energy Certificate (REC) purchase agreements in the United States (US), supporting the commissioning of additional renewable energy projects
Media Advisory
16 Jan 2024
Five Global Healthcare Leaders Secure Industry-first, Multi-party Agreement to Access Renewable Power in China
Five Global Healthcare Leaders Secure Industry-first, Multi-party Agreement to Access Renewable Power in China
Media Advisory
08 Jun 2023
Lonza Signs Ten-Year Virtual Power Purchase Agreement for Solar Electricity with IGNIS
Lonza Signs Ten-Year Virtual Power Purchase Agreement for Solar Electricity with IGNIS
Who we are
  • Company Overview
  • News & Media
  • Investor Relations
  • Sustainability
  • Careers
Quick Links
  • Reporting Center
  • Upcoming Events
  • Knowledge Center
  • Meet The Experts
  • Our Locations
  • California CCPA Notice
  • Transparency in Coverage
Get in touch
  • Contact Us
  • Regulatory Support
© 2026 Lonza. All rights reserved.
Cookie Settings | Terms and Conditions | Legal Disclaimer | Privacy Policy | Accessibility | Sitemap